Evaluation of immunotoxins containing single-chain ribosome- inactivating proteins and an anti-CD22 monoclonal antibody (OM124): In vitro and in vivo studies

British Journal of Haematology

Volumn 101, Issue 1, 1998, Pages 179-188

  Bolognesi, Andrea ^a   Tazzari, Pier Luigi ^b   Olivieri, Fabiola ^a   Polito, Letizia ^a   Lemoli, Roberto ^a   Terenzi, Adelmo ^c   Pasqualucci, Laura ^c   Falini, Brunangelo ^c   Stirpe, Fiorenzo ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Apoptosis; CD22 antigen; Immunotoxins; Non Hodgkin's B lymphomas; Ribosome inactivating proteins

Indexed keywords

CD22 ANTIGEN; IMMUNOTOXIN; MOMORDIN; MONOCLONAL ANTIBODY OM 124; POKEWEED ANTIVIRUS PROTEIN; RIBOSOME INACTIVATING PROTEIN; SAPORIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE MARROW CELL; BURKITT LYMPHOMA; CANCER IMMUNOTHERAPY; CELL VIABILITY; CONTROLLED STUDY; DRUG CONJUGATION; HUMAN; HUMAN CELL; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; STEM CELL;

EID: 0031980763     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1998.00665.x     Document Type: Article

References (36)

1. Amlot, P.L., Stone, M.J., Cunningham, D., Fay, J., Newman, J., Collins, R., May, R., McCarthy, M., Richardson, J., Ghetie, V., Ramilo, O., Thorpe, P.E., Uhr, J.W. & Vitetta, E.S. (1993) A phase 1 study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood, 82, 2624-2633.
2. Barbieri, L., Battelli, M.G. & Stirpe, F. (1993) Ribosome-inactivating proteins from plants. Biochimica et Biophysica Acta, 1154, 237-282.
3. Battelli, M.G., Polito, L., Bolognesi, A., Lafleur, L., Fradet, Y. & Stirpe, F. (1996) Toxicity of ribosome-inactivating proteins-containing immunotoxins to a human bladder carcinoma cell line. International Journal of Cancer, 65, 485-490.
4. Barbieri, L., Stoppa, C. & Bolognesi, A. (1987) Large-scale Chromatographic purfication of ribosome-inactivating proteins. Journal of Chromatography, 408, 235-243.
5. Bergamaschi, C., Perfetti, V., Tonon, L., Novella, A., Lucotti, C., Danova, M., Glennie, M.J., Merlini, G. & Cazzola, M. (1996) Saporin, a ribosome-inactivating protein used to prepare immunotoxins, induces cell death via apoptosis. British Journal of Haematology, 93, 789-794.
6. Bolognesi, A., Tazzari, P.L., Legname, G., Olivieri, F., Modena, D., Conte, R. & Stirpe, F. (1995) Anti-CD30 immunotoxíns with native and recombinant dianthin 30. Cancer Immunology and Immunotherapy, 40, 109-114.
7. Bolognesi, A., Tazzari, P.L., Olivieri, F., Polito, L., Falini, B. & Stirpe. F. (1996) Induction of apoptosis by ribosome-inactivating proteins and related immunotoxins. International Journal of Cancer, 68, 349-355.
8. Bolognesi, A., Tazzari, P.L., Tassi, C., Gromo, G., Gobbi, M. & Stirpe, F. (1992) Comparison of anti-lymphocyte immunotoxins containing different ribosome-inactivating proteins and antibodies. Clinical and Experimental Immunology, 89, 341-346.
9. Bonardi, M.A., Bell, A., French, R.R., Gromo, G., Hamblin, T., Modena, D., Tutt, A.L. & Glennie, M.J. (1992) Initial experience in treating human lymphoma with a combination of bispecific antibody and saporin. International Journal of Cancer, Supplement, 7, 73-77.
10. Bonardi, M.A., French, R.R., Amlot, P., Modena, D. & Glennie, M.J. (1993) Delivery of saporin to human B-cell lymphoma using bispecific antibody: targeting via CD22 but not CD19. CD37, or immunoglobulin results in efficient killing. Cancer Research, 53, 3015-3021.
11. Cortes, J.E. & Kantarjin, H.M. (1995) Acute lymphoblastic leukemia: a comprehensive review with emphasis on biology and therapy. Cancer, 76, 2393-2417.
12. Dinota, A., Barbieri, L., Gobbi, M., Tazzari, P.L., Rizzi, S., Bontadini, A., Bolognesi, A., Tura, S. & Stirpe, F. (1989) An immunotoxin containing momordin suitable for bone marrow purging in multiple myeloma patients. British Journal of Cancer, 60, 315-319.
13. Dorken, B., Moller, P, Pezzutto, A., Schwartz-Albiez, R. & Molden-hauer, G. (1990) B-cell antigens: CD22. Leucocyte Typing. IV. White Cell Differentiation Antigens (ed. by W. Knapp et al), pp. 63-64, Oxford University Press.
14. Ellman, G.L. (1959) Tissue sulphydryl group. Archives of Biochemistry and Biophysics, 82, 70-78.
15. Falini, B., Bolognesi, A., Flenghi, L., Tazzari, P.L., Broe, M.K., Stein, H., Durkop, H., Aversa, F., Corneli, P., Pizzolo, G., Barbabietola, G., Sabattini, E., Pileri, S., Martelli, M.F. & Stirpe, F. (1992) Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin. Lancet, 339, 1195-1196.
16. French, R., Worth, C.A., Browning, A., Stirpe, F., George, A.J.T. & Glennie, M.J. (1995) Delivery of the ribosome-inactivating protein, gelonin, to lymphoma cells via CD22 and CD38 using bispecific antibodies. British Journal of Cancer, 71, 986-994.
17. French, R.R., Bell, A.J., Hamblin, T.J., Tutt, A.L. & Glennie, M.J. (1996) Response of B-cell lymphoma to a combination of bispecific antibodies and saporin. Leukemia Research, 20, 607-617.
18. Ghetie, M.-A., May, R.D., Till, M., Uhr, J.W., Ghetie, V., Knowles, P.P., Relf, M., Brown, A., Wallace, P.M., Janossy, G., Amlot, P., Vitetta, E.S. & Thorpe, P.E. (1988) Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy. Cancer Research, 48, 2610-2617.
19. Ghetie, M.-A., Richardson, J., Tucker, T., Jones, D., Uhr, J.W. & Vitetta, E.S. (1991) Antitumor activity of Fab' and IgG anti-CD22 immunotoxins in disseminated human lymphoma grown in mice with severe combined immunodeficiency disease: effect on tumor cells in extranodal sites. Cancer Research, 51, 5876-5880.
20. Ghetie, M.-A., Tucker, T., Richardson, J., Uhr, J.W. & Vitetta, E.S. (1992) The antitumor activity of an anti-CD22 immunotuxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin. Blood, 80, 2315-2320.
21. Ghetie, M.-A., Tucker, T, Richardson, J., Uhr, J.W. & Vitetta, E.S. (1994) Eradication of minimal disease in severe combined immunodeficient mice with disseminated Daudi lymphoma using chemotherapy and an immunotoxin cocktail. Blood, 84, 702-707.
22. Gobbi, M., Cavo, M., Tazzari, P.L., Dinota, A., Tassi, C., Bontadini, A., Albertazzi, L., Miggiano, C., Rizzi, S., Rosti, G., Bolognesi, A., Stirpe, F. & Tura, S. (1989) Autologous bone marrow transplantation with immunotoxin-purged marrow for advanced multiple myeloma. European Journal of Haematology, 43, (Suppl. 51), 176-181.
23. Kehrl, J.H. (1995) In: Leucocyte Typing. V. CD22 Workshop Panel Report (ed. by S. F. Schlossman et al), pp. 523-525. Oxford University Press.
24. Pasqualucci, L., Flenghi, L., Terenzi, A., Bolognesi, A., Stirpe, F., Bigerna, B. & Falini, B. (1995) Immunotoxin therapy of haematological malignancies. Haematologica, 80, 546-556.
25. Sausville, E.A., Headlee, D., Stetler-Stevenson, M., Jaffe, E.S., Solomon, D., Figg, W.D., Herdt, J., Kopp, W.C., Rager, H., Steinberg, S.M., Gethie, V., Shindler, J., Uhr, J., Wittes, R.E. & Vitetta, E.S. (1995) Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study. Blood, 85, 3457-3465.
26. Senderowicz, A.M., Vitetta, E.S., Headlee, D., Ghetie, V., Uhr, J.W., Figg, W.D., Lush, R.M., Stetler-Stevenson, M., Kershaw, G., Kingma, D.W., Jaffe, E.S. & Sausville, H.A. (1997) Complete sustained response of a refractory. post-transplantation, large B-cell lymphoma to an anti-CD22 immunotoxin. Annals of Internal Medicine, 126, 882-885.
27. Shen, G-L., Li, J-A., Ghetie, M-A., Ghetie, V., May, R.D., Till, M., Brown, A.N., Relf, M., Knowles, P., Uhr, J.W., Janossy, G., Amlot, P., Vitetta, E.S. & Thorpe, P.E. (1988) Evaluation of four CD22 antibodies as ricin A-chain-containing immunotoxins for the in vivo therapy of human B-cell leukemias and lymphomas. International Journal of Cancer, 42, 792-797.
28. Strocchi, P., Barbieri, L. & Stirpe, F. (1992) Immunological properties of ribosome-inactivating proteins and of a saporin-IgG conjugate. Journal of Immunological Methods, 155, 57-65.
29. + lymphoma: in vitro evaluation. British Journal of Haematology, 81, 203-211.
30. Tazzari, P.L., Bolognesi, A., de Totero, D., Lemoli, K.M., Fortuna, A., Conter, R., Crumpton, M.J. & Stirpe, F. (1994) Immunotoxins containing saporin linked to different CD2 monoclonal antibodies: in vitro evaluation. British Journal of Haematology, 86, 97-105.
31. Trush, G.R., Lark, L.R., Clinchy, C. & Vitetta, E.S. (1996) Immunotoxins: an update. Annual Review of Immunology, 14, 49-71.
32. Urch, E.C., George, A.J.T., Stevenson, G.T., Bolognesi, A., Stirpe, F., Weller, R. & Glennie, M.J. (1991) Intra-thecal treatment of leptomeningeal lymphoma with immunotoxin. International Journal of Cancer, 47, 909-915.
33. Van Horssen, P.J., Preijers, F.W.M.B., Van Oosterhout, Y.V.J.M. & De Witte, T. (1996) Highly potent CD22-recombinant ricin A results in complete cure of disseminated malignant B-cell xenografts in SCID mice but fails to cure solid xenografts in nude mice. International Journal of Cancer, 68, 378-383.
34. Vitetta, E.S., Stone, M. Amlot, P., Fay, J., May, J., Till, M., Newman, J., Clark, P., Collins, R., Cunningham, D., Ghetie, V., Uhr, J.W. & Thorpe, P.E. (1991) Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Research, 51, 4052-4058.
35. Vitetta, E.S., Thorpe, P.E. & Uhr, J.W. (1993) Immunotoxins: magic bullets or misguided missiles? Immunology Today, 14, 252-259.
36. Zovickian, J. & Youle, R.J. (1988) Efficacy of intrathecal immunotoxin therapy in an animal model of leptomeningeal neoplasia. Journal of Neurosurgery, 68, 767-774.